Rubin, Daniel H. F. http://orcid.org/0000-0002-6753-4213
Ma, Kevin C.
Westervelt, Kathleen A.
Hullahalli, Karthik http://orcid.org/0000-0003-3064-2090
Waldor, Matthew K. http://orcid.org/0000-0003-1843-7000
Grad, Yonatan H. http://orcid.org/0000-0001-5646-1314
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (F30 AI160911, AI132120, AI156949, AI042347, AI132606, AI153521)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM007753)
Richard and Susan Smith Family Foundation (Odyssey award)
Article History
Received: 22 February 2022
Accepted: 28 October 2022
First Online: 5 January 2023
Competing interests
: Y.H.G. is on the scientific advisory board of Day Zero Diagnostics and consulted for GlaxoSmithKline. Y.H.G. has received funding from Merck and Pfizer. None of these competing interests has a bearing on this project. The other authors declare no competing interests.